Addex entered an exclusive collaboration and license agreement with Merck, through its affiliate Merck Sharp & Dohme Research, in late 2007, to develop a new class of orally available drugs, initially as candidates for the treatment of Parkinson’s disease and potentially other undisclosed indications
The new agreement allows Addex to regain rights to intellectual property and know-how and can continue the program independently.
Addex CEO Bharatt Chowrira said they believe that mGluR4 is a highly attractive target for treating Parkinson’s and other serious diseases.
"We remain committed to pursuing mGluR4 PAM for Parkinson’s and other diseases," Chowrira said.